Clinical Study

A Phase II Single-Arm Trial To Investigate Tepotinib In Stage IIIb/Iv Adenocarcinoma Of The Lung With Met Exon 14 (Metex14) Skipping Alterations After Failure Of At Least One Prior Active Therapy, Including A Platinum-Doublet-Containing Regimen

Posted Date: Feb 18, 2018

  • Investigator: John Morris
  • Co-Investigator: Andrea Collins
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to learn how effective the study drug, tepotinib, is at stopping the growth and spread of lung cancer that did not respond to previous treatment with a specific type of chemotherapy. This study will also measure the safety of the study drug and the side effects; how the body processes the study drug; and how the study drug affects quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug. This research will involve collecting an additional blood sample.

Criteria:

To Be Eligible To Participate, Study Participants Must Have Adenocarcinoma Of The Lung Which Has Been Previously Treated (Including Chemotherapy) But The Cancer Did Not Respond To The Treatment. This Type Of Lung Cancer Is Associated With A Specific Change In Part Of Your Dna (Genes).

Keywords:

Lung Cancer, Ms200095-0022, Lung, Cancer, Phase Ii

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu

  • Search Clinical Studies

  • Research in the News

    Therapy After Surgical Removal of Rare Tumors May Not Increase Survival

    Results of an analysis show that additional therapy delivered after surgicalremoval of a rare type of gastrointestinal tumor does not increase survivalrates for patients.